{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:14:07Z","timestamp":1793783647363,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.10.007","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T18:59:13Z","timestamp":1445799553000},"page":"104-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["The management and treatment of children with Fabry disease: A United States-based perspective"],"prefix":"10.1016","volume":"117","author":[{"given":"Robert J.","family":"Hopkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn A.","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria H.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2015.10.007_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: a systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0035","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2215\/CJN.04631007","article-title":"Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients","volume":"3","author":"Rademacher","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0080","unstructured":"Fabry Registry. Fabry Annual Report 2010. Available at: http:\/\/www.fabry.org\/fsig.nsf\/PDFs\/PDFsR\/$File\/2010_Annual_Report.pdf. Accessed: April 17, 2015."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0090","series-title":"Fabry Disease: Perspectives From 5Years of FOS","article-title":"Organization and technical aspects of FOS \u2014 the Fabry Outcome Survey","author":"Hernberg-St\u00e5hl","year":"2006"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-10-116","article-title":"Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)","volume":"10","author":"Ramaswami","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0135","first-page":"7","article-title":"Fetal pathology in Fabry's disease and mucopolysaccharidosis type I","volume":"34","author":"Elleder","year":"1998","journal-title":"Cesk. Patol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ki.2012.169","article-title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C","volume":"82","author":"Schwartz","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0155","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00467-006-0358-1","article-title":"Glomerular filtration rate measurement and estimation in chronic kidney disease","volume":"22","author":"Schwartz","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.08091109","article-title":"Assessment of renal pathology and dysfunction in children with Fabry disease","volume":"5","author":"Ramaswami","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0165","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1681\/ASN.2013050557","article-title":"Longitudinal changes in estimated and measured GFR in type 1 diabetes","volume":"25","author":"de Boer","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112188","article-title":"Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease","volume":"9","author":"Mauer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0180","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.02150212","article-title":"Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988\u20132010","volume":"7","author":"T\u00f8ndel","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/8904_2013_222","article-title":"Early cardiac changes in children with Anderson-Fabry disease","volume":"11","author":"Havranek","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0190","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","article-title":"Cognitive dysfunction and depression in Fabry disease: a systematic review","volume":"37","author":"Bolsover","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0200","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajmg.b.32297","article-title":"The neurocognitive impact of Fabry disease on pediatric patients","volume":"168B","author":"Bugescu","year":"2015","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0205","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","article-title":"Neuropathic symptoms and findings in women with Fabry disease","volume":"119","author":"Laaksonen","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","article-title":"Functional and structural nerve fiber findings in heterozygote patients with Fabry disease","volume":"145","author":"Torvin M\u00f8ller","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0215","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","article-title":"Physiological characterization of neuropathy in Fabry's disease","volume":"26","author":"Luciano","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0220","first-page":"491","article-title":"The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)\u2014investigation of symptomatic and presymptomatic patients","volume":"75","author":"Morgan","year":"1990","journal-title":"Q. J. Med."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0225","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mus.20174","article-title":"Functional assessment of A delta and C fibers in patients with Fabry's disease","volume":"30","author":"Valeriani","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0230","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","article-title":"Characterization of pain in Fabry disease","volume":"30","author":"\u00dc\u00e7eyler","year":"2014","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0235","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1526-4637.2008.00470.x","article-title":"Detection of a characteristic painful neuropathy in Fabry disease: a pilot study","volume":"9","author":"Maag","year":"2008","journal-title":"Pain Med."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0240","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1445-5994.2007.01366.x","article-title":"Neurology of Fabry disease","volume":"37","author":"Low","year":"2007","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0245","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","article-title":"Diagnosis of Fabry disease via analysis of family history","volume":"17","author":"Laney","year":"2008","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","article-title":"Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel","volume":"11","author":"Burlina","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00108-012-3204-5","article-title":"Pain therapy for Fabry's disease","volume":"54","author":"Sommer","year":"2013","journal-title":"Internist"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0265","doi-asserted-by":"crossref","unstructured":"N. Attal, G. Cruccu, R. Baron, M. Haanp\u00e4\u00e4, P. Hansson, T.S. Jensen, T. Nurmikko; European Federation of Neurological Societies, EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision, Eur. J. Neurol. 17 (2010) 1113-e88.","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"10.1016\/j.ymgme.2015.10.007_bb0270","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-004-1462-8","article-title":"The co-existence of Fabry and celiac diseases: a case report","volume":"19","author":"T\u00fcmer","year":"2004","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0275","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0280","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy","volume":"85","author":"Banikazemi","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0290","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"Borgwardt","year":"2013","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0295","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1651-2227.2010.02101.x","article-title":"Safety of agalsidase alfa in patients with Fabry disease under 7years","volume":"100","author":"Ramaswami","year":"2011","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0300","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","article-title":"Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease","volume":"156","author":"Schiffmann","year":"2010","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0310","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alpha in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2015.10.007_bb0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"9","author":"Schiffmann","year":"2014","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T08:51:38Z","timestamp":1537260698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215300652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1096719215300652"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management and treatment of children with Fabry disease: A United States-based perspective","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}